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Abstract
Vaccination with naked DNA holds great promise but immunogenicity needs to be improved. DNA constructs encoding
bivalent proteins that bind antigen-presenting cells (APC) for delivery of antigen have been shown to enhance T and B cell
responses and protection in tumour challenge experiments. However, the mechanism for the increased potency remains to
be determined. Here we have constructed DNA vaccines that express the fluorescent protein mCherry, a strategy which
allowed tracking of vaccine proteins. Transfected muscle fibres in mice were visualized, and their relationship to infiltrating
mononuclear cells could be determined. Interestingly, muscle fibers that produced MHC class II-specific dimeric vaccine
proteins with mCherry were for weeks surrounded by a localized intense cellular infiltrate composed of CD45+, MHC class II+
and CD11b+ cells. Increasing numbers of eosinophils were observed among the infiltrating cells from day 7 after
immunization. The local infiltrate surrounding mCherry+ muscle fibers was dependent on the MHC II-specificity of the
vaccine proteins since the control, a non-targeted vaccine protein, failed to induce similar infiltrates. Chemokines measured
on day 3 in immunized muscle indicate both a DNA effect and an electroporation effect. No influence of targeting was
observed. These results contribute to our understanding for why targeted DNA vaccines have an improved immunogenicity.
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Introduction
Vaccination with naked DNA holds great promise for number
of reasons such as ease of genetic construction, low cost, rapidity of
mass production, high stability, and an attractive safety profile
[1,2]. However, the immunogenicity of plasmid DNA needs to be
improved, and especially in larger animals and humans. Among
major contributors to enhanced efficiency are vector design and
optimization, and delivery methods such as gene gun [3],
electroporation (EP) [4,5], liposomes [6], nano particles [7], and
viral capsids [1,2,8]. As concerns the immunogenicity-enhancing
effect of EP, employed in the present study, it has been described
that changing the field strength [9] or the field orientation (uni- or
bipolar) [9] influence the number of transfected muscle fibres and
thus the production of protein encoded by the transfected gene.
Apart from enhancing transfection efficacy, electroporation may
induce inflammatory infiltrates [10,11,12], and enhance produc-
tion of proinflammatory cytokines [11]; factors that could
contribute to potent immunoactivation.
A promising strategy to improve immune responses to protein
antigen is to target antigen to antigen-presenting cells (APC).
Given their exquisite specificity, antibodies are excellent for this
purpose. In pioneering studies, antigens were chemically coupled
to antibodies specific for APC; such antigen-antibody conjugates
were shown to enhance immune responses [13,14,15]. Later,
antigens have been genetically introduced into the C regions of
recombinant antibodies engineered to express APC-specific
variable regions [16,17,18,19,20,21,22,23]. Antigens have been
attached to the carboxy terminal tail of Fab fragments [16] or
complete IgG [23], approaches which have certain limitations
such as monovalency [16] and bulkiness [23]. In another strategy,
9–37 aa long antigenic peptides corresponding to T cell epitopes
substitute loop regions between b-strands in the C-domain
[17,18,22,24]. The latter strategy has the advantage that the
antibody structure is basically maintained with normal half lives in
vivo [20]. The drawback is that the short antigenic peptides often
lack conformational determinants and are poor at stimulating B
cells and antibody responses. Moreover, the inserted peptides only
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fit to certain of the polymorphic MHC molecules in a species,
which makes the T cell epitope insertion strategy less attractive as
a general vaccine in outbred populations.
To overcome these limitations of previously recombinant
antibodies, we generated a novel type of immunoglobulin-based
molecules (vaccibodies) that are homodimers, targeting APC by
single-chain variable fragment (scFv) specific for mouse MHC class
II [25], CD40 [26] and TLR2 [27], or natural ligands like
chemokines (MIP-1a and RANTES) [28], and deliver large
genetically attached antigens with intact B-cell determinants
[25,28] for induction of potent T and B cell responses. Similar
to complete antibodies [29], vaccibodies [25] can be delivered by
injection of plasmid DNA into skeletal muscle followed by
electroporation. Transfected muscle cells synthesize and secrete
vaccibodies that can be found in serum and that are absorbed by
APC [25]. Thus, antigen-primed APC as well as activation of
CD4+ T cells can be demonstrated in draining lymph nodes,
resulting in protective immunity against tumor challenges [25,28].
However, the events taking place in the muscle with such DNA
vaccines that encode APC-targeted proteins have not been
studied. To address this issue we have here equipped the MHC
II-specific vaccibodies with fluorescent mCherry, which makes the
vaccine molecules easy to track. Fibers that produce MHCII-
specific vaccine proteins become surrounded by infiltrating cells
that stain positive for CD45, MHC class II, and CD11b. Large
amounts of eosinophils were observed among the infiltrating cells
from day 7. Chemokines measured on day 3 after treatment
indicates an effect of both DNA-injection and electroporation.
Materials and Methods
Mice
BALB/c mice were bought from Taconic (Ry, Denmark), and
were used for experiments between 6 and 10 weeks of age. The
study was approved by the Norwegian Animal Research
Committee (Oslo, Norway) (Permit number; Id-281 (2005), Id-
666 (2007)).
Constructions of mCherry vaccibody and mCherry-
containing plasmids
Vaccibodies were constructed as explained by Fredriksen et al.
[25]. The gene encoding mCherry [30] was kindly given to us by
prof. Tsien (University of California, San Diego, CA). The
mCherry gene was amplified from the pRSET-B vector by PCR,
using primers introducing either 59-BsmI, 39-BamHI, or 59-SfiI
and 39-SfiI restriction sites. The mCherry gen was cloned either
into pLNOH2 between BsmI and BamHI or as antigenic unit in
the vaccibody format between SfiI sites. In addition, a pLNOH2
plasmid expressing mCherry-His-Tag (for purification of native
mCherry protein) was made, using a different 59-BsmI primer.
(Primers: restriction enzyme sites are underlined and the stop and
start codons are indicated in bold. Gene codons of mCherry are
depicted in capital letters. Introducing mCherry into pLNOH2 59-
mCherry BsmI; ggtgtgcattcc atg GTG AGC AAG GGC GAG
GAG GAT AAC ATG 39-mCherry BamHI; ggtgggatcc tca CTT
GTA CAG CTC GTC CAT GCC GCC G. Introducing
mCherry with His-Tag into pLNOH2 59-His mCherry BsmI;
ggtgtgcattcc atg CGG GGT TCT CAT CAT CAT CAT CAT
CAT GG. Cloning mCherry into antigenic site of ; 59-mCherry
SfiI; ta ggcctcggtggcctg atg GTG AGC AAG GGC GAG GAG
GAT AAC ATG. 39-mCherry SfiI; ta ggccctgcaggcc tca CTT
GTA CAG CTC GTC CAT GCC GCC). mCherry had either
targeting units specific for MHC class II (I-Ed, scFv cloned from
14-4-4S B cell hybridoma) or were specific for the hapten 4-
hydroxy-3-iodo-5-nitro-phenylacetyl (NIP scFv cloned from B1-8
hybridoma) [31]. These two mCherry containing vaccibodies are
denoted aMHCII-mCherry and aNIP-mCherry, respectively.
Transfections
Plasmid DNA encoding mCherry vaccibodies were transiently
transfected into HEK293 cells by use of Lipofectamine 2000
(Invitrogen), using the protocol supplied by the manufacturer.
Transfection efficiency of mCherry vaccibodies was monitored by
Axiovert Leica microscopy with TRITC filter sets, and by testing
supernatants in ELISAs.
ELISA
ELISAs to evaluate the secretion of vaccibodies from transfected
cells were performed using either an anti-mCherry antibody (clone
1 or clone 2 denoted a-mCherry.1 or a-mCherry.2) [32] or anti-
human CH3 (clone A57H) or NIP-BSA (NIP conjugated to BSA)
(1 mg/ml) for capture. As detection antibodies, either biotinylated
anti-mCherry (a-mCherry.1-bio or a-mCherry.2-bio) [32] or
biotinylated anti-human CH3 (a-hCH3-bio, clone HP6017) were
used, followed by incubation with alkaline phosphatase-conjugated
streptavidin and p-nitrophenyl phosphate substrate. For detection
of anti-mCherry antibodies in sera of immunized mice, microtiter
plates were coated with purified recombinant mCherry. Serum
samples were serially diluted and incubated overnight, followed by
incubation with alkaline phosphatase-conjugated anti-murine IgG
(Fc-specific, cat. no. A2429, Sigma) or biotinylated IgG subclass-
specific antibodies (anti-murine IgG1 (clone 10.9), anti-murine
IgG2a (clone 8.3)). Threshold for end point titers was set to 26 the
absorbance value of the negative controls (sera from mice given
PBS).
Gel electrophoresis
The samples were diluted in SDS-containing buffer and run on
4–20% Tris-Glycine polyacrylamide gels (Invitrogen). To reduce
the disulfide bonds, some samples were treated with b-mercapto-
ethanol for 3 min at 95uC before electrophoresis. SeeBlue Plus2
Pre-Stained Standard (Invitrogen) was used to indicate the
molecular weights. The proteins were blotted onto a polyvinyl
fluoride membrane (Biorad) by 100 V for 1 h at 4uC. Milk and
casein (5% and 1%, respectively) in 0.1% Tween 20 was used to
block the membrane before incubation over night at 4uC with
biotinylated anti-mCherry followed by incubation with streptavi-
din-conjugated HRP (Amersham Bioscience). The protein bands
were developed by a chemiluminescent peroxidase substrate,
Lumigen (GE Healthcare) and images were acquired by Kodak
image station 2000R.
Productions and purification of recombinant mCherry
pLNOH2 vector encoding mCherry with His-tag sequence
expressed from a CMV promoter was stably transfected into NS0
cells by electroporation. Positive colonies were selected using
Axiovert Leica microscopy with TRITC filter sets, and cloned by
limiting dilution. Clones selected for strong fluorescence were
expanded in roller bottles and grown for 7 days. Supernatants
were harvested and mCherry proteins affinity purified on Ni-NTA
superflow resin (Qiagen.) The eluted protein was dialysed against
PBS 0.05% azid and stored as aliquots (1 mg/mL) 220uC.
DNA injection and electroporation
BALB/c mice 6 to 10 weeks of age were immunized with DNA
plasmids. Two different immunization methods were used in this
study. (i) Animals immunized for measuring elicitation of anti-
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mCherry antibodies, or induction of chemokines in muscle, were
DNA-injected and electroporated as follows: 6 to 8 weeks old
BALB/c were anesthetized (Hypnorm Dormicum), their legs were
shaved, and conductive gel was applied on the skin prior to
injection of 50 ml of plasmids (purified with EndoFree plasmid kit
(Qiagen); in concentration 1.0 mg/ml in 0.9% NaCl) in the femoral
quadriceps muscle. Immediately after plasmid injection, electro-
poration was performed by use of the Elgen electroporator device
equipped with a caliper electrode (Elgen, Inovio Biomedical Co.,
PA). The settings were: bipolar pulses of 100 mV 60.2 ms with
pulse sequence train and pulse sequence being 10 and 1000,
respectively (1061000-pulses protocol.) (ii) Animals immunized for
in vivo microscopy and specimens for immunohistochemistry were
immunized as follows: 6 to 8 weeks old BALB/c were anesthetized,
soleus muscle was surgically exposed, and 10 ml of DNA solution
(1.0 mg/ml in 0.9% NaCl) was injected into the centre of the
muscle with a 701 Hamilton syringe (Hamilton, Reno, NV, USA).
Subsequently, 5 trains of 1000 bipolar pulses (200 ms in each
direction) with a peak-to-peak voltage of 10 V were run across the
muscle, applied directly to the surface of the muscle by two silver
electrodes (561000-pulses protocol). After treatment the dermis
was sutured [33].
Histopathology and immunohistochemistry
Mice were killed 7 days after DNA/EP immunization, and
injected soleus muscle was excised and immediately frozen in
OCT medium in isopropanol/nitrogen bath. Frozen muscles were
cut into 5 mm sections, air dried, and fixed for 5 minutes in EtOH.
Fixed sections were stained with hematoxylin and eosin (HE)
before dehydration, mounting, and examination by microscopy.
Sections for immunohistochemistry were air-dried before being
packed in aluminium foil and frozen (220uC). Slides were placed
in a hydration chamber and 30% inactivated rat serum was added
to sections for 1 hour, before biotinylated or FITC-conjugated
antibodies were added for 1 hour, followed by streptavidin-
Alexa488 or anti-fluorescein-Alexa488, respectively. Some slides
were also stained with rabbit anti-laminin followed by anti-rabbit-
Cy5. Primary antibodies used were anti-CD45-FITC (Clone 30-
F11), anti-MHC class II-bio (TIB120 hybridoma, home made),
anti-CD11b-FITC (Clone M1/70), and anti-laminin (cat.
no. L9393, Sigma). Secondary antibodies used were Streptavi-
din-Alexa488 (cat. no. S-11223 Invitrogen), anti-fluorescein/
Oregon Green-Alexa488 (cat. no. A-11096 Invitrogen), and anti-
Rabbit-Cy5 (cat. no. ab6564, Abcam). Isotype controls used were
Rat IgG2a-FITC (cat. no. 0117-02, SouthernBiotech), Rat IgG2a-
FITC (cat. no. 0118-02, SouthernBiotech), Rat IgG2b-bio (cat.
no. 0118-08, SouthernBiotech) and Hamster IgG1-bio (cat.
no. 553951, BD Pharmingen).
Microscopy and in vivo imaging
HE stained slides were examined and photographed on a Leica
DMRB microscope with PL Fluotar oil-immersion objectives,
connected to Leica DFC320 camera, and analyzed with Leica
Image Manager and Photoshop CS4. Examination of immuno-
histochemistry slides and in vivo imaging were performed on a
fixed-stage fluorescence microscope (Olympus BX50WI) with
water-immersion objectives, adjustable halogen 12V (100W) lamp
and non-adjustable quicksilver lamp. SIT camera (Hamamatsu
C2400–08) coupled to an image processor (Hamamatsu ARGUS-
20) and a Macintosh computer running Adobe Photoshop were
used for photographs and analysis. In vivo imaging was performed
on anesthetized animals by placing them on a heated plate and
surgically opening the dermis to expose the muscle. Muscle was
covered with Ringer-acetate, in some experiments including DAPI
to visualize nuclei, and held in place with a coverslip mounted
2 mm above the muscle. The heated platform was placed on the
microscope work platform and viewed through water-immersion
objectives with long working distances. The lamp was operated at
3–5 V in order to avoid phototoxicity. For details see [34,35,36].
Quantification of cytokines produced by plasmid-
injected muscle
BALB/c mice were injected with plasmids encoding either
aMHCII-mCherry or aNIP-mCherry (or PBS as negative control)
into each quadriceps, followed by EP. Mice were sacrificed 3 or 21
days later, injected muscles were removed, and pooled for each
animal. Muscles were washed in PBS, before adding approx. 1 ml
RPMI1640 to a total volume of 1.5 ml, before disruption in an
omni mixer. The homogenized solution was centrifuged, and
supernatant collected and filtered trough a 0.45 mm HT Tuffryn
membrane (PALL life science). To avoid repeated freeze-thaw
cycles, 50 ml of each sample was aliquoted and kept at 270 uC
until analysis. Cytokine and chemokine levels were measured using
mouse-specific Bio-plex 23-plex assay (Biorad laboratories, Her-
cules, CA, US). Samples were adjusted to 0.5% BSA (Biotest,
Dreieich, Germany), as were cytokine standards and background
blanks. The assays were carried out according to the manufactur-
er’s instructions. Measurements and data analysis were performed
on Bio-Plex system, powered by xMAP technology by Luminex,
operated with Bio-Plex Manager 4.1 software (BioRad Laborato-
ries). The instrument was calibrated with the CAL2 settings (LOW
RP1 target value) using Bio-Plex calibration beads (BioRad
Laboratories). Samples were analyzed as single samples, whereas
standards were analyzed in duplicates.
Statistical analysis
All statistical analysis were carried out using GraphPad Prism,
version 4 (GraphPad Software, San Diego, CA, USA). The
different groups subjected to cytokine analyses were compared and
analysed using the Mann-Whitney test. ELISA data were analysed
by using two-tailed t-test. p,0.05 were considered statistically
significant.
Results
Construction of mCherry-containing vaccibodies
In order to track the vaccibodies as well as to identify their site
of production, DNA encoding the fluorescent protein mCherry
was inserted into the vaccibody format. mCherry was chosen
because of favourable properties like short maturation time
(15 minutes) which allows it to be visualized soon after translation;
low pKa (,4.5) which make it traceable after endocytosis; and
good brightness and resistance to bleaching which are preferable
properties in microscopy. In addition, the red shifted emission
contributes to less disturbance of tissue auto fluorescence, and its
monomeric structure and high tolerance for both N- and C-
terminal fusions were attractive features for expression as part of
vaccibody [37]. mCherry was genetically introduced into the
antigenic unit of vaccibodies specific for either MHC class II (I-E)
(denoted aMHCII) or the hapten 5-iodo-4-hydroxy-3-nitrophe-
nacetyl (NIP) (denoted aNIP) (Figure 1a). Anti-NIP is anticipated
not to recognize any molecules in mice, and was therefore used as
non-targeted control.
In vitro characterization of the vaccine molecules
To examine whether the vaccine molecules were secreted,
Western blotting and ELISAs were performed on supernatants
harvested from transfected HEK293 cells. Under non-reducing
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conditions, bands of approximately 140 kDa were detected while
under reducing conditions bands of approximately 70 kDa were
observed (Figure 1b). These sizes are consistent with predicted
molecular weights and suggest that the mCherry-containing
vaccibodies mainly are secreted as dimers. A battery of ELISAs
verified that the vaccibodies were secreted from transfected
HEK293 (Figure 1c). ELISAs confirmed that the non-targeted
control, aNIP-mCherry, bound to NIP-conjugated BSA (Fig-
ure 1c). Moreover, the aMHCII-mCherry bound to spleen
sections from BALB/c (Figure 1d) but not from C57BL/6 mice
(data not shown), consistent with maintenance of I-E MHC II
specificity. aNIP-mCherry did not bind spleen sections (Fig-
ure 1d). These results demonstrate that the two different targeting
units maintained their specificity in the vaccibody format.
The mCherry signal is associated with only a few nuclei in
a muscle fiber
We wanted to visualize the vaccine proteins in the muscles after
DNA injection and electroporation (EP). In order to increase the
control over the electroporation procedure, and to make it easier
to localize the transfected muscle fibers, we did sight-guided DNA-
injection and EP of muscle soleus, followed by suture. Before
analysis by fluorescence microscopy, the mice were anesthetized,
and the skin reopened to expose the muscle. Muscle fibers
transfected with mCherry vaccibodies emitted fluorescence
(Figure 2a). Nuclei were visualized by bathing the muscle during
microscopy in Ringer-acetate solution containing DAPI (a
fluorescent dye that binds DNA) (Figure 2b).
One muscle fiber/myocyte of muscle soleus, being approxi-
mately 7 mm long may contain around 400 nuclei [38].
Figure 1. Characterization of mCherry-containing vaccibodies. (a) Schematic drawing of the vaccibody format [25] which consists of three
functional units: a targeting unit, a dimerization unit (hinge h1 and h4 joined to the CH3 domain derived from human IgH chain c3) followed by an
antigenic unit. DNA encoding aMHCII or aNIP (non-targeted control) was inserted into the targeting unit, and DNA encoding mCherry or scFv of the
myeloma protein M315 (negative control) was inserted into the antigenic unit. (b) The mCherry-containing vaccibodies form dimers. DNA encoding
the vaccibodies was transfected into HEK293 cells, and the supernatants were either untreated (-ME) or treated with mercaptoethanol (+ME) prior to
SDS-PAGE. Blotted proteins were detected by an anti-mCherry antibody [32]. (c) DNA encoding the vaccibodies or mCherry was transfected into
HEK293 cells, and the supernatants were analyzed by ELISA as indicated. (d) aMHCII-mCherry but not aNIP-mCherry bound to sections of spleen from
BALB/c. Stippled lines indicate the border between the red pulpa (RP) and the white pulpa (WP).
doi:10.1371/journal.pone.0108069.g001
Figure 2. Muscle fibers transfected with aNIP-mCherry visual-
ized in vivo in mice. DNA encoding aNIP-mCherry was injected into
the soleus muscle followed by EP. One day later, the dermis was
opened and mCherry (red) indicative of vaccibody expression was
visualized by fluorescence microscopy of live muscle in vivo in
anesthetized BALB/c mice. (a) Fluorescence microscopy of longitudinal,
mid section of soleus muscle. The muscle belly boundary is indicated by
dotted lines. Scale bar, 1 mm. (b) Fluorescence microscopy of two
transfected muscle fibers. The dotted lines indicate the boundaries of
one muscle fiber. DAPI was added to the muscle surface for staining of
the nuclei. Scale bar, 50 mm.
doi:10.1371/journal.pone.0108069.g002
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Microscopy of live muscle showed strong mCherry signal
juxtaposed to only one or a few nuclei in a long muscle fiber
(Figure 2b, day 7 after DNA injection). mCherry signal was
observed at the poles of nuclei, probably reflecting the Golgi
apparatus, and in round structures within the muscle fiber. In
general, there was a gradient of the mCherry signal in the fiber,
being highest at the poles of the nuclei and waning with increased
distance (Figure 2b).
MHC II-targeted vaccibody enhances antibody responses
and recruits immune cells
The vaccibody format was originally designed with the intent to
target antigens to APCs, aiming to increase immune responses
[25]. To examine whether the MHC II-targeted vaccibodies
carrying mCherry in the antigenic unit induced higher levels of
anti-mCherry antibodies, DNA encoding either aMHCII- or
aNIP-mCherry was injected intramuscularly in quadriceps of
BALB/c mice followed by EP. (Note that the electroporation
procedure applied to the soleus and quadriceps muscles were
different, see Materials and Methods.) Both types of vaccibodies
induced antibody responses, however, the kinetics of the responses
differed (Figure 3a). Anti-mCherry antibodies were detectable
already at day 14 following immunization with aMHCII-
mCherry. Antibodies following immunization with aNIP-mCherry
appeared later but at day 40 the levels were similar to those
induced by aMHCII-mCherry (Figure 3a).
In further experiments, we wanted to examine whether the
difference in kinetics was reflected by local reactions in the muscle
at the site of DNA injection. Soleus muscles from BALB/c mice
immunized with aMHCII-mCherry were harvested after 7 days,
cut into sections and stained with an antibody specific for CD45,
which is expressed by cells of hematopoietic origin. Microscopy at
low magnification revealed relatively few spots with mCherry
signal, and an increased number of CD45+ cells present in focal
areas throughout the muscle (Figure 3b and 3c, left image). To
further identify the localization of the CD45+ cells, sections were
immunostained with an antibody to laminin, a glycoprotein found
in the basement membrane surrounding muscle fibers. The
infiltrating CD45+ cells were localized outside of the basement
membrane (Figure 3c, left image). Sections from muscles of
BALB/c mice immunized with the non-targeted control (aNIP-
mCherry) had comparatively few infiltrating CD45+ cells (Fig-
ure 3c, right image). Injection of the aMHCII-mCherry or aNIP-
mCherry resulted in approximately the same number of mCherry-
expressing muscle fibers (Figure 3c, and data not shown). Thus,
these experiments suggest that the aMHCII-mCherry induces a
focal inflammatory reaction at the injection site that depends on
the targeting specificity.
To study the mCherry signal in more detail, we made
longitudinal and cross sections of soleus muscle from mice
immunized with MHC class II-targeted mCherry vaccibody
(Figure 3d). Similar to the observation in vivo (Figure 2b), strong
mCherry signal was found perinuclear to only a few nuclei within
the length of a single muscle fiber, indicating a segmented
expression of the mCherry vaccibodies within a fiber (Figure 3d).
Thus, mCherry observed in a cross section most likely underes-
timate the number of transfected fibers, because a fiber that
appears negative may nevertheless express mCherry at a level
above or below the section, as illustrated in an interpretative
drawing (Figure 3e). Nevertheless, in further experiments, when
characterizing the infiltrates, we chose to investigate the immedi-
ate surroundings of fibers that expressed mCherry.
Mononuclear and multilobulated cells are recruited
following immunization with MHC class II-targeted
vaccibodies
To characterize the CD45+ cellular infiltrate, muscle soleus was
harvested 2, 4, and 7 days after immunization and stained with
HE. aMHCII-mCherry induced cellular infiltrates present already
2 days after immunization. The infiltrating cells were localized
between muscle fibers and the number increased with time
(Figure 4a, b). The magnitude of the cellular infiltrate depended
on MHC II-targeting since only few cells were observed between
the fibers following delivery of aNIP-mCherry (Figure 4b, right
panel). The increased cellular infiltration caused by aMHCII-
mCherry, compared to aNIP-mCherry was also observed at day
13 (data not shown).
The infiltrate observed after DNA/EP immunization with
aMHCII-mCherry, segregated the fibers and disrupted normal
muscle morphology (Figure 4b, longitudinal section, left panel). At
all time points, the infiltrate consisted of mononuclear cells as well
as granulocyte-like cells with multilobulated nuclei (Figure 4a–c).
Interestingly, by day 7, numerous cells with morphology similar to
eosinophils (multilobulated nuclei and eosinophilic granula) were
observed in the tissue (Figure 4c). The eosinophilic infiltrates
depended on MHC class II-targeting, since there were no
infiltrates of eosinophils following immunization with the aNIP-
mCherry (Figure 4b, and data not shown).
Characterization of the cellular infiltrate by
immunostaining
aMHCII-mCherry or aNIP-mCherry DNA was delivered to
the soleus muscle of BALB/c immediately followed by EP. The
muscle was harvested at different time-points after immunization
(day 3, 7, and 13, in altogether 8 experiments including a total of
30 mice). Immunostaining of muscles harvested 7 days post
immunization, is presented in Figure 5. Similar to what we
observed in previous experiments, focal infiltrates were only
observed after immunization with the aMHCII-mCherry and not
with the aNIP-mCherry (Figure 5). We stained sections for
CD11b, a marker of monocytes/macrophages, DCs, neutrophils
and natural killer cells. A major fraction of the cells had an
intermediate signal for CD11b while a minor fraction of the cells
were CD11b bright. In addition, we observed that most of the
infiltrating cells were MHC II+ (TIB120).
Cytokines in immunized muscle tissue
To examine whether there was a correlation between cellular
infiltration and the cytokine milieu, we measured the levels of
cytokines by use of Bio-Plex analyses of homogenized muscles
from DNA/EP-immunized BALB/c. Because HE staining
revealed an increasing number of infiltrating cells on days 2 and
4 after immunization with the targeted vaccine (Figure 4), we used
muscle harvested on day 3 for the cytokine analysis.
Several observations could be made. First, injection of PBS/EP
resulted in an increase in 13 out of 23 cytokines, when measured
on day 3 compared to day 21 (Figure 6, Table I). Based on the
assumption that values obtained on day 21 represent base line
levels, our observations indicate that EP and/or the injection
volume is a potent method for induction of several pro-
inflammatory cytokines. Moreover, when compared to levels
obtained by PBS/EP, injection of DNA/EP significantly boosted
the expression of 5 out of the 13 cytokines (MCP-1, RANTES, IL-
12p40, MIP-1a, MIP-1b). These data suggest that either DNA
itself and/or produced vaccibody protein promoted expression of
the 5 cytokines. The levels of 3 of the 5 cytokines, IL-12p40, MIP-
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Figure 3. Immunization with aMHCII-mCherry followed by EP enhances antibody levels and cellular infiltrates in the muscle. (a) MHC
II-targeting promotes antibody responses at early time points. PBS or DNA encoding mCherry or (either aMHCII-mCherry or aNIP-mCherry) was
injected into quadriceps of BALB/c mice immediately followed by EP (day 0). Blood samples were harvested at the indicated time points. Serum
antibody titers were determined by ELISA employing mCherry as coat. (Each symbol represents mean value of 2 or 3 mice, bars indicates 6SD.)
Student’s t-test of endpoint titers induced by aMHCII-mCherry in comparison to aNIP-mCherry gave P-values of 0.01 (IgG) and 0.04 (IgG2a) at day 14
(asterisk). (b) DNA encoding mCherry-containing vaccibodies was injected into the soleus muscle followed by EP. The muscle was harvested after 7
days, and cross sections of whole muscle were stained by use of anti-CD45 (clone 30-F11). Nuclei were stained by DAPI (blue). Scale bar, 1 mm. (c)
DNA was given to BALB/c as described in b. After 7 days, soleus muscle was harvested and cross sections stained for CD45 (green) and laminin (blue).
Red color in the left and right merged micrographs are indicative of aMHCII-mCherry and aNIP-mCherry, respectively. Scale bars, 50 mm. (d) Muscle
harvested on day 7 from mice immunized with aMHCII-mCherry. A longitudinal and a cross section is shown in the top and bottom image,
respectively. mCherry indicative of aMHCII-mCherry is shown in red and nuclei (DAPI-staining) in blue. White stippled lines indicate a muscle fiber/
myocyte that expresses aMHCII-mCherry. Scale bar, 50 mm. (e) Interpretative drawing of a muscle fiber positive for mCherry (red color). The mCherry
signal is concentrated around two nuclei (blue), and in puncta in the vicinity. Stippled lines in the drawing denoted a, b, c, and d, represent possible
section levels. Some sections will contain both infiltrating cells and mCherry signal (b and d) while in others, only the infiltrating cells will be visible (a
and c).
doi:10.1371/journal.pone.0108069.g003
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1a and MIP-1b were enhanced following delivery of DNA, but not
following PBS injection, suggesting that electroporation was not
sufficient to enhance the levels of these 3 cytokines. Finally, none
of the 23 cytokines that were measured showed significant
differences after immunization with aMHCII-mCherry or aNIP-
mCherry. The results are summarized in Table 1, which also
includes a comparison with results published by others.
Discussion
In this study we show that introducing mCherry in the
vaccibody format does not appreciably alter the antigenic or
fluorescence properties of mCherry, neither does it reduce the
specificity of the targeting unit for MHC class II. Furthermore, we
show that transfected muscle cells emit mCherry fluorescence
already one day post-immunization. Interestingly, by in vivo
microscopy on DNA-injected and electroporated (EP) mice, we
observed that only one or a few nuclei per transfected muscle fiber
produced mCherry. mCherry accumulated in vesicle-like struc-
tures in proximity of apparently DNA-transfected nuclei. To what
extent the segmented intracellular expression within the muscle
fiber is reflected in concentration differences when vaccibodies are
secreted to the extracellular fluid is unknown.
It is unclear whether mononuclear cells become transfected
after DNA injection and electroporation of muscle [10,39,40].
One study [39] demonstrated that DNA injection into tibialis
muscle of mice resulted in DNA uptake both by mononuclear cells
and muscle cells. However, only the muscle cells were found to
express the transgene, and the expression was enhanced by
electroporation. Importantly, the uptake of DNA by mononuclear
cells was not influenced by electroporation, and transfected
mononuclear cells did not transcribe the transfected gene.
Moreover, plasmid DNA was only found in vesicles, indicating
endocytosis but not transfection. A later study [40] failed to detect
transfected mononuclear cells positive for leucocyte surface
markers located in muscle. Moreover, transgene-encoded mRNA
was not detected in draining LN. In the most recent study [10],
transfected mononuclear cells in the muscle were found to be
satellite cells, staining positive for muscle-specific marker desmin,
and negative for leucocyte specific surface markers CD3 and
CD68. The above mentioned studies are consistent with the
present study, since we have yet to find mCherry protein expressed
in other cells than muscle fibers themselves, thus, we have no
evidence of transfected APC. This observation is consistent with
the finding that vaccibodies targeted to MHC-II increased anti-
mCherry antibody responses over that seen with non-targeted
vaccibody DNA. The targeting effect indicates that vaccibodies
secreted by transfected muscle cells bind MHC class II molecules
on APC for induction of immune responses. Stated otherwise, if
transfection of mononuclear cells had been a major pathway for
induction of enhanced immune responses upon DNA/EP
immunization, no targeting effect would have been observed.
The electroporation procedure by itself is reported to induce
inflammation [10,11], production of chemokines and cytokines
Figure 4. Immunization with aMHCII-mCherry leads to recruit-
ment of mononuclear and multilobulated cells. DNA encoding
aNIP-mCherry or aMHCII-mCherry was injected into the soleus muscle
of BALB/c mice, followed by EP. Muscles were harvested at the
indicated time points, flash-frozen and HE-stained. Representative
images are shown. (a) Muscle injected with aMHCII-mCherry harvested
on day 2 (left) and day 4 (right). Corner insets show high magnification
of framed areas. (b) Comparison of muscle 7 days after immunization
with aMHCII-mCherry or aNIP-mCherry. Longitudinal sections (upper
row) and cross-sections (lower row) of muscles are shown. (c) Higher
magnification of HE-stained section of soleus muscle harvested 7 days
after immunization with aMHCII-mCherry. The infiltrate consisted of
cells containing large nuclei, visible nucleoli, and sparse cytoplasm. In
addition, we observed a large number of multilobulated cells with
eosin-positive granula (arrows).
doi:10.1371/journal.pone.0108069.g004
Figure 5. Characterization of infiltrating cells by immunostain-
ing. The soleus muscle was harvested from BALB/c mice 7 days after
injection of DNA encoding aNIP-mCherry or aMHCII-mCherry followed
by EP. Immunostaining was performed with an antibody towards
CD11b (clone M1/70) or MHC class II (clone TIB120). CD11b and MHCII
are shown in green, nuclei in blue (DAPI), and mCherry in red indicative
of aNIP-mCherry (upper row) or aMHCII-mCherry (bottom row). Scale
bar, 80 mm.
doi:10.1371/journal.pone.0108069.g005
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[11], and influx of a mixture of inflammatory cells [12,40]. In
addition, it has been described that injection of DNA, in absence
of electroporation, induces upregulation of MCP-1 in muscle, and
influx of IFN-c secreting cells [41]. Although these studies differ in
methodology and chemokines/cytokines measured (Table 1),
there is an emerging picture that both electroporation and DNA
injection can induce chemokine/cytokine secretion from muscle
cells. Our results confirm and extend these previous findings by
testing many more chemokines and cytokines. In addition, a
novelty of our study is that DNA injection and electroporation
appears to act in concert to improve expression of certain
cytokines (IL-12p40, MIP-1a, MIP-1b). It may be noted that some
cytokines (MIP-1a, RANTES, IL-8, MIG, IP-10, MIP-3a),
overlapping with those described herein to be upregulated upon
DNA/EP vaccination (Figure 6, Table 1), are also found to be
increased in inflammatory diseases in muscle [42].
Interestingly, the different versions of vaccibodies, either
aMHCII-mCherry or aNIP-mCherry, did not influence on the
expression of cytokines in the muscle. This was surprising since the
targeted and non-targeted vaccibodies differed in their abilities to
induce antibodies and T cells (present study and [25]). These
results indicate that the mechanism for enhanced immunogenicity
of aMHCII-mCherry most probably must be sought in the
draining lymph node. This suggestion is consistent with previous
results demonstrating that aMHCII-vaccibody delivered as DNA/
EP induces antigen-priming of APC and proliferation of CD4+ T
cells in draining lymph nodes [25] (but not in spleen or non-
draining lymph node). Moreover, we have recently found that B
cell hybridomas are easily obtained by fusing cells from draining
lymph nodes but not spleen of targeted vaccibody immunized
mice, indicating that also B cell responses primarily take place in
draining lymph nodes [32].
Even though the differences in immunogenicity between
aMHCII-mCherry and aNIP-mCherry primarily appears to take
place in the draining lymph node, clear cut differences were found
in the immunized muscle for the two vaccibody versions. Thus,
targeted vaccibodies induced more pronounced local infiltrates of
macrophage-like CD45+MHCII+CD11b+cells, neutrophils and
late-invading eosinophils. We failed to detect significant numbers
of CD19+ B cells and CD11c+ dendritic cells (unpublished results).
The latter preliminary observation appears to be at variance with
a previous study [12] that described the mixed inflammatory
infiltrate induced by DNA/EP to consist of CD19+ B-cells,
CD3+CD4+ T-cells, CD11b+ macrophages and CD11c+ dendritic
cells. The lack off infiltration of CD11c+ or CD19+ cells in the
present study could by a result of methodology of DNA/EP
Figure 6. Cytokines in the muscle following intramuscular
injection of DNA and EP. BALB/c were immunized in quadriceps with
either PBS or DNA encoding aMHCII-mCherry or aNIP-mCherry, as
indicated. After 3 days, muscles from DNA-injected (n = 6/group) and
PBS-injected (n = 4/group) were harvested and homogenized before
analysis by use of Bio-Plex. Baseline levels, indicated by stippled
horizontal lines, represent values measured in muscle isolated 21 days
after injection of PBS and electroporation (n = 4). Each symbol
represents data from one mouse. Mean values are indicated by
horizontal lines. Mann-Whitney test was used to calculate p-values.
doi:10.1371/journal.pone.0108069.g006
Table 1. Induction of cytokines by electroporation, and further enhancement by injection of DNA.
Study EP induced cytokines
DNA enhancement of EP induced
cytokines
Enhancement only by DNA/EP in
combination
aThis study IL-2, IL-3, IL-4, IL-5, IL-17, G-CSF,
TNF-a, KC, MCP-1, Rantes
MCP-1, Rantes IL-12p40, MIP-1a, MIP-1b
bPeng et al.[11] MIP-1a, MIP-1b, MIP-1c, IP-10, MCP-2, XCL-1
dFigarella et al.[42] TNF-a, IL-1b
a50 mg of DNA was injected in each quadriceps immediately followed by electroporation (Elgen, Inovio). 3 days later, 23 cytokines were measured in homogenized
muscle (Bio-Rad, Bio-plex 23-assay). Cytokines not increased by either EP or DNA/EP were: IL-1a, IL-1b, IL-6, IL-9, IL-10, IL-12p70, IL-13, INF-c, GM-CSF, and Eotaxin.
bPeng et al. stimulated tibialis anterior muscle in BALB/c mice with electroporation, and isolated muscle at different time points 2, 4 h and 1, 3d after stimulation.
Isolated RNA and measured chemokines with cDNA array.
dFigarella et al. stimulated gluteus muscle with different combinations of electroporation, non-electroporation, DNA, PBS and empty DNA vector. TNF-a and IL-1b were
measured using ELISA on samples isolated at 3 h.
doi:10.1371/journal.pone.0108069.t001
Inflammatory Cell Recruitment by Targeting to APC
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e108069
immunization or a real absence. Further studies are clearly
warranted to clarify this issue.
We have not been able to define a molecular mechanism for
why targeted vaccibodies induced infiltrates, and why the
infiltrates appeared to surround the aMHCII-mCherry producing
fiber. In particular, we found no differences in levels of 23
cytokines in muscle, related to targeting or non-targeting of
vaccibodies (see above). Perhaps subtle differences, unknown
factors, or effects masked by the EP-induced inflammation,
operate in the vicinity of muscle cells producing aMHCII-
mCherry. It is tempting to speculate that ligation of MHC II on
a few resident APC in muscle by aMHCII-mCherry, results in
unknown chemoattractants being produced. However, as stated
above, we have so far failed to observe binding of vaccibodies to
MHCII+ APC in muscle.
Heredia et al. [43] has recently shown that eosinophils infiltrate
cardiotoxin-injured muscle in mice and orchestrate, in an IL-4/IL-
13 driven fashion, the differentiation of fibro/adipocyte progen-
itors (satellite cells) into myocytes required for complete regener-
ation of muscle tissue. In the present study, the late-appearing
eosinophilic infiltrate is associated with aMHCII-mCherry. We
postulate that this attraction of eosinophils is related to ligation of
MHC class II on resident or infiltrating APC. We have failed to
observe upregulation of eotaxin or IL-5, but hypothesize that
existence a factor ‘‘X’’ could cause influx of eosinophils. It is well
known that eosinophils are a major player of innate type 2
protection. It is therefore interesting to notice that the increase in
antibodies caused by MHC-II targeting is mainly of the IgG1
subclass, which is known to be associated with Th2 responses. It is
tempting to speculate that provision of MHCII ligation, e.g. by
antibodies, can be used therapeutically in muscle diseases to
induce infiltration of eosinophils and enhance muscle regenera-
tion.
In summary (Figure 7), the increased immunogenicity of
MHCII targeted vaccine molecules for T cells [25,44] and B cells
is probably explained at the level of the draining lymph node. The
transfected muscle cells primarily serve as production factories for
secreted vaccine proteins. There are two non-exclusive explana-
tions for how the vaccine molecules are transported from muscle to
the draining lymph node. One possibility is that the vaccine
molecules are transported as soluble molecules with afferent
lymphatic vessels and bind to MHC II+ APC in the draining
lymph node. Another possibility is that the targeted vaccine
proteins bind the MHC II+ cells that accumulate in the vicinity of
the transfected muscle cell. Such vaccibody-primed APC could
then migrate to the draining lymph node where they could
stimulate T and B cells. We have, however, thus far failed to detect
that aMHCII-mCherry bind to MHC II+ infiltrating cells in
muscle in vivo. This failure could be due to a too low sensitivity of
fluorescence microscopy. Regardless of mechanism of transport, a
fraction of the MHCII-specific vaccine molecules must have
maintained intact conformation since stimulation of B cells is
enhanced.
We postulate that MHC II-targeted vaccibodies is efficient at
stimulating B cells due to formation of APC-B cell synapses in
draining lymph nodes, as previously described in vitro [45].
MHCII-specific vaccine molecules could efficiently bridge APC
and B cells. Bivalency of vaccibodies could contribute to synapse
formation by increasing avidity for both APC and B cells
(Figure 7). As concerns T cell help, MHC II-targeted vaccibody
has previously been shown to increase antigen-priming of APC
and enhance CD4+ T cell activation [25]. In addition, the B cells
could via their BCR accumulate vaccine protein, process it, and
present Ag-peptides on their MHCII molecules to CD4+ T cells
(Figure 7). Thus, an APC-vaccibody-B cell synapse should concur
with high levels of T cell help. As a consequence, B cells stimulated
via its BCR by arrayed vaccine proteins in an APC-B cell synapse,
and at the same time receiving strong T cell help, could efficiently
develop into antibody secreting plasma cells (Figure 7). The
combination of APC-targeting, bivalency of protein, and delivery
as DNA, holds promise for establishment of a new generation of
subunit vaccines.
Figure 7. Interpretative drawing of proposed mechanism of action of targeted versus non-targeted DNA vaccines. Injection of DNA
(1a,1b) and electroporation (2a,2b) have an adjuvant effect by inducing an inflammatory reaction in muscle resulting in elevated levels of chemokines
(3). Transfected muscle cells produce (4, red colour) and secrete the targeted (5, upper) and non-targeted (5, lower) vaccine molecules. By an unknown
mechanism, the targeted vaccibody induce an infiltration after .2 days predominantly composed of macrophages/DC, neutrophils and eosinophils
(6). Targeted vaccibodies could drain to lymph node either unbound or bound to MHC II+ APC, but this remains to be determined. In contrast, non-
targeted vaccibodies probably drain to lymph node as unbound molecules. In draining lymph nodes, targeted vaccibodies induce APC-B cell
synapses and generation of T helper cells [25], resulting in strong stimulation of antigen specific B cells and generation of antibody secreting plasma
cells (7). By contrast non-targeted vaccibodies do not induce APC-B cell synapses, and generation of T helper cells is poor [25] (8), resulting in
inefficient plasma cell generation and antibody production.
doi:10.1371/journal.pone.0108069.g007
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